Lista de obras -

A Germline DNA Polymorphism Enhances Alternative Splicing of theKLF6Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk

article

A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response.

artículo científico publicado en 2008

Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma

artículo científico publicado en 2018

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.

artículo científico publicado en 2017

All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase

artículo científico publicado en 2015

Bisphosphonates inactivate human EGFRs to exert antitumor actions

artículo científico publicado en 2014

Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation.

artículo científico publicado en 2011

Challenges and Reinterpretation of Antibody-Based Research on Phosphorylation of Tyr307 on PP2Ac

scientific article published on 01 March 2020

Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia"

artículo científico publicado en 2019

Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534].

artículo científico publicado en 2015

Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1.

artículo científico publicado en 2004

Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity

artículo científico publicado en 2020

Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma

artículo científico publicado en 2019

Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.

artículo científico publicado en 2006

E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor.

artículo científico publicado en 2006

Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing ⬇️

artículo científico publicado el 27 de agosto de 2012

IKKα negatively regulates ASC-dependent inflammasome activation

artículo científico publicado en 2014

In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma

scientific article published on 05 February 2007

Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors

artículo científico publicado en 2019

Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer.

artículo científico publicado en 2008

KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma.

artículo científico publicado en 2007

KLF6 degradation after apoptotic DNA damage.

artículo científico publicado en 2006

KLF6 is one transcription factor involved in regulating acid ceramidase gene expression.

artículo científico publicado en 2005

KLF6-SV1 Drives Breast Cancer Metastasis and Is Associated with Poor Survival ⬇️

artículo científico publicado el 23 de enero de 2013

KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model.

artículo científico publicado en 2009

KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.

artículo científico publicado en 2008

Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer.

artículo científico publicado en 2004

Kruppel-like transcription factor 6 regulates inflammatory macrophage polarization

artículo científico publicado en 2014

Krüppel cripples prostate cancer: KLF6 progress and prospects

artículo científico publicado en 2003

Krüppel-like factor 6 regulates mitochondrial function in the kidney

artículo científico publicado en 2015

Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex

artículo científico publicado en 2020

Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression

artículo científico publicado en 2010

Lulling the Cancer Cell into an Eternal Sleep

scientific article published on 01 April 2019

Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression

artículo científico publicado en 2019

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

artículo científico publicado en 2018

Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator

artículo científico publicado en 2017

Protein phosphatase 2A Aα regulates Aβ protein expression and stability

scientific article published on 22 February 2019

Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers

artículo científico publicado en 2019

Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45)

scientific article published on 27 September 2019

Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer

artículo científico publicado en 2014

RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth

scientific article published on 04 March 2019

Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.

artículo científico publicado en 2008

Reengineered tricyclic anti-cancer agents.

artículo científico publicado en 2015

Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation.

artículo científico publicado en 2005

Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer

artículo científico publicado en 2014

Ribosomal protein S19 expression during erythroid differentiation.

artículo científico publicado en 2002

Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones.

artículo científico publicado en 2005

Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer

artículo científico publicado en 2018

Specificity of research antibodies: "trust is good, validation is better".

artículo científico publicado en 2017

Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts

scientific article published on 11 September 2018

Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6.

artículo científico publicado en 2004

Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.

artículo científico publicado en 2005

Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma.

artículo científico publicado en 2009

Targeting PP2A in cancer: Combination therapies

scientific article published on 01 September 2018

Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.

artículo científico publicado en 2012

The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis

artículo científico publicado en 2019

The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease

artículo científico publicado en 2008

The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells

artículo científico publicado en 2019

The Transcriptional Activator Krüppel-like Factor-6 Is Required for CNS Myelination

artículo científico publicado en 2016

The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice.

artículo científico publicado en 1995

The impact of phosphatases on proliferative and survival signaling in cancer

artículo científico publicado en 2018

Therapeutic Targeting of PP2A.

artículo científico publicado en 2017

Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53.

artículo científico publicado en 2004

microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition.

artículo científico publicado en 2014

Lista de obras de

A Germline DNA Polymorphism Enhances Alternative Splicing of theKLF6Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk

A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response.

Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.

All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase

Bisphosphonates inactivate human EGFRs to exert antitumor actions

Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation.

Challenges and Reinterpretation of Antibody-Based Research on Phosphorylation of Tyr307 on PP2Ac

Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia"

Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534].

Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1.

Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity

Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma

Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.

E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor.

Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing ⬇️

IKKα negatively regulates ASC-dependent inflammasome activation

In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma

Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors

Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer.

KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma.

KLF6 degradation after apoptotic DNA damage.

KLF6 is one transcription factor involved in regulating acid ceramidase gene expression.

KLF6-SV1 Drives Breast Cancer Metastasis and Is Associated with Poor Survival ⬇️

KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model.

KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.

Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer.

Kruppel-like transcription factor 6 regulates inflammatory macrophage polarization

Krüppel cripples prostate cancer: KLF6 progress and prospects

Krüppel-like factor 6 regulates mitochondrial function in the kidney

Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex

Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression

Lulling the Cancer Cell into an Eternal Sleep

Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator

Protein phosphatase 2A Aα regulates Aβ protein expression and stability

Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers

Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45)

Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer

RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth

Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.

Reengineered tricyclic anti-cancer agents.

Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation.

Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer

Ribosomal protein S19 expression during erythroid differentiation.

Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones.

Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer

Specificity of research antibodies: "trust is good, validation is better".

Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts

Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6.

Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.

Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma.

Targeting PP2A in cancer: Combination therapies

Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.

The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis

The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease

The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells

The Transcriptional Activator Krüppel-like Factor-6 Is Required for CNS Myelination

The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice.

The impact of phosphatases on proliferative and survival signaling in cancer

Therapeutic Targeting of PP2A.

Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53.

microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition.